Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239332227> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4239332227 endingPage "661" @default.
- W4239332227 startingPage "661" @default.
- W4239332227 abstract "Irritable bowel syndrome is an extremely common disorder affecting approximately 10-20% of the population of North America and Europe. This disorder is characterized by abdominal pain and altered bowel habit. The altered bowel habit can take a number of forms. These include a predominant diarrhea form, a form with constipation and one in which patients alternate between diarrhea and constipated forms of the disorder. Irritable bowel syndrome to date has not been associated with any excess mortality. However, the morbidity associated with irritable bowel syndrome is quite high. This mainly takes on the form of impairment in health-related quality of life, interference with activities of daily living and a considerable degree of human suffering. Likewise, the economic impact of irritable bowel syndrome is not trivial and has been estimated to be between US$20 to 30 billion in the United States alone. In an effort to address this common disabling disorder, a number of new drugs have been developed. One of the latest is cilansetron, which is a competitive type 3 serotonin (5-HT3) receptor antagonist. In phase III trials, cilansetron has been shown to be efficacious for the relief of a wide spectrum of symptoms related to irritable bowel syndrome with diarrhea both in male and female patients. By and large, cilansetron is extremely well tolerated and highly efficacious. The most common side effect of cilansetron is constipation, which is seen in 3-12% of subjects at 6 months. Ischemic colitis, a side effect associated with previous drugs of this class, has been seen in eight subjects (six women and two men) to date. All of these ischemic colitis events have been self-limited and did not require surgery. Because of its high degree of efficacy, the fact that it is well tolerated by the overwhelming majority of patients and that it shows efficacy in both genders, cilansetron represents a major advance in the treatment of irritable bowel syndrome with diarrhea predominance." @default.
- W4239332227 created "2022-05-12" @default.
- W4239332227 creator A5020562589 @default.
- W4239332227 creator A5088271082 @default.
- W4239332227 date "2005-01-01" @default.
- W4239332227 modified "2023-10-15" @default.
- W4239332227 title "Cilansetron" @default.
- W4239332227 doi "https://doi.org/10.1358/dot.2005.41.10.920427" @default.
- W4239332227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16389408" @default.
- W4239332227 hasPublicationYear "2005" @default.
- W4239332227 type Work @default.
- W4239332227 citedByCount "6" @default.
- W4239332227 countsByYear W42393322272012 @default.
- W4239332227 crossrefType "journal-article" @default.
- W4239332227 hasAuthorship W4239332227A5020562589 @default.
- W4239332227 hasAuthorship W4239332227A5088271082 @default.
- W4239332227 hasConcept C126322002 @default.
- W4239332227 hasConcept C159110408 @default.
- W4239332227 hasConcept C2778260677 @default.
- W4239332227 hasConcept C2778271842 @default.
- W4239332227 hasConcept C2778561856 @default.
- W4239332227 hasConcept C2779134260 @default.
- W4239332227 hasConcept C2779802037 @default.
- W4239332227 hasConcept C2779951463 @default.
- W4239332227 hasConcept C2780955771 @default.
- W4239332227 hasConcept C2781112942 @default.
- W4239332227 hasConcept C2908647359 @default.
- W4239332227 hasConcept C71924100 @default.
- W4239332227 hasConcept C90924648 @default.
- W4239332227 hasConcept C99454951 @default.
- W4239332227 hasConceptScore W4239332227C126322002 @default.
- W4239332227 hasConceptScore W4239332227C159110408 @default.
- W4239332227 hasConceptScore W4239332227C2778260677 @default.
- W4239332227 hasConceptScore W4239332227C2778271842 @default.
- W4239332227 hasConceptScore W4239332227C2778561856 @default.
- W4239332227 hasConceptScore W4239332227C2779134260 @default.
- W4239332227 hasConceptScore W4239332227C2779802037 @default.
- W4239332227 hasConceptScore W4239332227C2779951463 @default.
- W4239332227 hasConceptScore W4239332227C2780955771 @default.
- W4239332227 hasConceptScore W4239332227C2781112942 @default.
- W4239332227 hasConceptScore W4239332227C2908647359 @default.
- W4239332227 hasConceptScore W4239332227C71924100 @default.
- W4239332227 hasConceptScore W4239332227C90924648 @default.
- W4239332227 hasConceptScore W4239332227C99454951 @default.
- W4239332227 hasIssue "10" @default.
- W4239332227 hasLocation W42393322271 @default.
- W4239332227 hasLocation W42393322272 @default.
- W4239332227 hasOpenAccess W4239332227 @default.
- W4239332227 hasPrimaryLocation W42393322271 @default.
- W4239332227 hasRelatedWork W191441647 @default.
- W4239332227 hasRelatedWork W2042153138 @default.
- W4239332227 hasRelatedWork W2058272774 @default.
- W4239332227 hasRelatedWork W2350043805 @default.
- W4239332227 hasRelatedWork W2370025972 @default.
- W4239332227 hasRelatedWork W2393734156 @default.
- W4239332227 hasRelatedWork W2802379714 @default.
- W4239332227 hasRelatedWork W2944101099 @default.
- W4239332227 hasRelatedWork W3032741126 @default.
- W4239332227 hasRelatedWork W2740497042 @default.
- W4239332227 hasVolume "41" @default.
- W4239332227 isParatext "false" @default.
- W4239332227 isRetracted "false" @default.
- W4239332227 workType "article" @default.